The first-of-its-kind oral pill could replace injectable medications for some patients with psoriasis, dermatologists say.

On March 17, HSBC analyst Morten Herholdt raised the firm’s price recommendation on Johnson & Johnson (NYSE:JNJ) to $280 from ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's oral pill for psoriasis, the company said.

AbbVie Inc. (NYSE:ABBV) is one of the debt free halal stocks to buy. On March 3, at the TD Cowen 46th Annual Health Care Conference, AbbVie Inc.

Belgium’s largest drugmaker UCB has announced positive topline data from the BE BOLD trial assessing Bimzelx bimekizumab) versus Skyrizi (risankizumab) in adults living with active psoriatic arthritis ...

Amgen’s Otezla was the subject of a spoof pharma ad that ran during SNL’s most recent episode. The ad, featuring actor Ryan Gosling, poked fun at the supposed mystery behind the medication and its ...

In early March 2026, AbbVie reported positive topline Phase 3 AFFIRM data showing risankizumab (SKYRIZI) subcutaneous induction achieved significantly higher clinical remission and endoscopic response ...

In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI ®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for ...

AbbVie ABBV reported 9% revenue growth in 2025 and provided 2026 guidance of $67 billion in revenue (10% growth) and a 150-basis-point improvement in adjusted operating margin. Shares fell 4% in ...

Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising superstar Skyrizi. Despite the fall of what was once the world’s top-selling ...